Non-surgical treatment options for symptomatic uterine leiomyomas

Current Women's Health Reviews

Volumn 6, Issue 2, 2010, Pages 146-160

  Tantibhedhyangkul, Julierut ^a   Behera, Millie A ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Asoprisnil; Fibroids; Gonadotropin releasing hormone agonists; Hormones; Magnetic resonance guided focused ultrasound surgery; Mifepristone; Nsaids; Oral contraceptives; Progestins; Selective estrogen receptor modulators; Transvaginal temporary uterine artery occlusion; Uterine artery embolization

Indexed keywords

EID: 84871404910     PISSN: 15734048     EISSN: 18756581     Source Type: Journal    
DOI: 10.2174/157340410791321390     Document Type: Article

References (144)

1. Chen CR, Buck GM, Courey NG, Perez KM, Wactawski-Wende J. Risk factors for uterine fibroids among women undergoing tubal sterilization. Am J Epidemiol 2001; 153(1): 20-26.
2. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188(1): 100-107.
3. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 2003; 111(8): 1037-1054. ** This is an excellent review article about etiology and pathogene sis of fibroids.
4. st ed. Elsevier Co. 2006; pp. 683-695.
5. th ed. 2003; pp. 753-798.
6. Keshavarz H, Hillis SD, Kieke BA, Marchbanks PA. Hysterectomy Surveillance --- United States, 1994--1999. Morbid Mortal Wkly Rep 2002; 51 (SS05): 1-8.
7. Marshall LM, Spiegelman D, Goldman MB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998; 70(3): 432-439. *This large prospective study found a positive correlation between the diagnosis of fibroid and oral contraceptive used.
8. Chiaffarino F, Parazzini F, La Vecchia C, Marsico S, Surace M, Ricci E. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynaecol 1999; 106(8): 857-860.
9. Parazzini F, Negri E, La Vecchia C, Fedele L, Rabaiotti M, Luchini L. Oral contraceptive use and risk of uterine fibroids. Obstet Gyne-col 1992; 79(3): 430-433.
10. Orsini G, Laricchia L, Fanelli M. Low-dose combination oral contraceptives use in women with uterine leiomyomas. Miner Ginecol 2002; 54(3): 253-261.
11. Friedman AJ, Daly M, Juneau-Norcross M, Gleason R, Rein MS, LeBoff M. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years. Hum Reprod 1994; 9(9): 1618-1625.
12. Venkatachalam S, Bagratee JS, Moodley J. Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study. J Obstet Gynaecol 2004; 24(7): 798-800.
13. American College of Obstetricians and Gynecologists. ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol 2008; 112(2 Pt 1): 387-400.
14. ESHRE Capri Workshop Group. Intrauterine devices and intrauter-ine systems. Hum Reprod Update 2008; 14(3): 197-208.
15. Murat Naki M, Tekcan C, Ozcan N, Cebi M. Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia among women of reproductive age without a significant regression in the uterine and leiomyoma volumes. Fer-til Steril 2009. [Epub ahead of print]
16. Rosa e Silva JC, de Sa Rosa e Silva, A.C., et al. Use of a levonorg-estrel-releasing intrauterine device for the symptomatic treatment of uterine myomas. J Reprod Med 2005; 50(8): 613-617.
17. Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menor-rhagia: a prospective controlled trial. Gynecol Obstet Invest 2005; 59(1): 29-35.
18. Mercorio F, De Simone R, Di Spiezio Sardo A, et al. The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia. Contraception 2003; 67(4): 277-280.
19. Starczewski A, Iwanicki M. Intrauterine therapy with levonorg-estrel releasing IUD of women with hypermenorrhea secondary to uterine fibroids. Ginekol Pol 2000; 71(9): 1221-1225.
20. Fong YF, Singh K. Effect of the levonorgestrel-releasing intrauter-ine system on uterine myomas in a renal transplant patient. Contraception 1999; 60(1): 51-53.
21. Lethaby A, Augood C, Duckitt K, Farquhar C. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2007; (4): CD000400.
22. Makarainen L, Ylikorkala O. Primary and myoma-associated me-norrhagia: role of prostaglandins and effects of ibuprofen. Br J Ob-stet Gynaecol 1986; 93(9): 974-978.
23. Ke LQ, Yang K, Li J, Li CM. Danazol for uterine fibroids. Coch-rane Database Syst Rev 2009;(3): CD007692.
24. Coutinho EM, Goncalves MT. Long-term treatment of leiomyomas with gestrinone. Fertil Steril 1989; 51(6): 939-946.
25. Coutinho EM. Treatment of large fibroids with high doses of gestrinone. Gynecol Obstet Invest 1990; 30(1): 44-47.
26. Gutmann JN, Corson SL. GnRH agonist therapy before myomec-tomy or hysterectomy. J Minim Invasive Gynecol 2005; 12(6): 529-537
27. Chegini N, Verala J, Luo X, Xu J, Williams RS. Gene expression profile of leiomyoma and myometrium and the effect of go-nadotropin releasing hormone analogue therapy. J Soc Gynecol In-vestig 2003; 10(3): 161-171.
28. Luo X, Ding L, Xu J, Williams RS, Chegini N. Leiomyoma and myometrial gene expression profiles and their responses to go-nadotropin-releasing hormone analog therapy. Endocrinology 2005; 146(3): 1074-1096.
29. Olive DL, Lindheim SR, Pritts EA. Non-surgical management of leiomyoma: impact on fertility. Curr Opin Obstet Gynecol 2004; 16(3): 239-243.
30. Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprol-ide Study Group. Obstet Gynecol 1991; 77(5): 720-725.
31. Schlaff WD, Zerhouni EA, Huth JA, Chen J, Damewood MD, Rock JA. A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata. Obstet Gynecol 1989; 74(6): 856-862.
32. Palomba S, Affinito P, Tommaselli GA, Nappi C. A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata. Fertil Steril 1998; 70(1): 111-118.
33. Morris EP, Rymer J, Robinson J, Fogelman I. Efficacy of tibolone as add-back therapy in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids. Fertil Steril 2008; 89(2): 421-428.
34. Palomba S, Affinito P, Di Carlo C, Bifulco G, Nappi C. Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profiles. Fer-til Steril 1999; 72(5): 889-895.
35. Palomba S, Orio F, et al. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas. Hum Reprod 2004;19(6): 1308-1314.
36. Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev 2001; (2): CD000547. ** The Cochrane database evaluated the benefint of using short term GnRH analogue prior to hysterectomy or myomectomy.
37. Chen W, Yoshida S, Ohara N, Matsuo H, Morizane M, Maruo T. Gonadotropin-releasing hormone antagonist cetrorelix down-regulates proliferating cell nuclear antigen and epidermal growth factor expression and up-regulates apoptosis in association with enhanced poly(adenosine 5'-diphosphate-ribose) polymerase expression in cultured human leiomyoma cells. J Clin Endocrinol Me-tab 2005; 90(2): 884-892.
38. Kwon JY, Park KH, Park YN, Cho NH. Effect of cetrorelix acetate on apoptosis and apoptosis regulatory factors in cultured uterine leiomyoma cells. Fertil Steril 2005; 84(5): 1526-1528.
39. Flierman PA, Oberye JJ, van der Hulst VP, de Blok S. Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix. BJOG 2005; 112(5): 638-642.
40. Felberbaum RE, Kupker W, Krapp M, Gehl B, Ludwig M, Die-drich K. Preoperative reduction of uterine fibroids in only 16 days by administration of a gonadotrophin-releasing hormone antagonist (Cetrotide). Reprod Biomed Online 2001; 3(1): 14-18.
41. Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SS. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993; 76(2): 513-517.
42. Bagaria M, Suneja A, Vaid NB, Guleria K, Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust N Z J Obstet Gy-naecol 2009; 49(1): 77-83.
43. Engman M, Granberg S, Williams AR, Meng CX, Lalitkumar PG, Gemzell-Danielsson K. Mifepristone for treatment of uterine leio-myoma. A prospective randomized placebo controlled trial. Hum Reprod 2009; 24(8): 1870-1879.
44. Carbonell Esteve JL, Acosta R, Heredia B, Perez Y, Castaneda MC, Hernandez AV. Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 2008; 112(5): 1029-1036.
45. Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 2006; 108(6): 1381-1387.
46. Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 2003; 101(2): 243-250.
47. Yang Y, Zheng S, Li K. Treatment of uterine leiomyoma by two different doses of mifepristone. Zhonghua Fu Chan Ke Za Zhi 1996; 31(10): 624-626.
48. Murphy AA, Morales AJ, Kettel LM, Yen SS. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil Steril 1995; 64(1): 187-190.
49. Reinsch RC, Murphy AA, Morales AJ, Yen SS. The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. Am J Obstet Gyne-col 1994; 170(6): 1623-1627; discussion 1627-8.
50. Eisinger SH, Fiscella J, Bonfiglio T, Meldrum S, Fiscella K. Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata. Eur J Obstet Gynecol Reprod Biol 2009; 146(2): 215-218.
51. Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol 2005; 12(3): 227-233.
52. Chwalisz K, Garg R, Brenner R, Slayden O, Winkel C, Elger W. Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs). Reprod Biol Endocrinol 2006; 4(Suppl 1): S8.
53. Chen W, Ohara N, Wang J, et al. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 2006; 91(4): 1296-1304.
54. Morikawa A, Ohara N, Xu Q, et al. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. Hum Reprod 2008; 23(4): 944-951.
55. Wang J, Ohara N, Wang Z, et al. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells. Hum Reprod 2006; 21(7): 1869-1877.
56. Chwalisz K, Elger W, Stickler T, Mattia-Goldberg C, Larsen L. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum Reprod 2005; 20(4): 1090-1099.
57. Chwalisz K, Larsen L, Mattia-Goldberg C, et al. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 2007; 87(6): 1399-1412.
58. Williams AR, Critchley HO, Osei J, et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod 2007; 22(6): 1696-1704.
59. Wilkens J, Chwalisz K, Han C, et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 2008; 93(12): 4664-4671.
60. Palomba S, Sammartino A, Di Carlo C, et al. Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertil Steril 2001; 76(1): 38-43.
61. Palomba S, Orio F, Jr., Morelli M, et al. Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study. J Clin Endocrinol Metab 2002; 87(8): 3603-3608.
62. Jirecek S, Lee A, Pavo I, Crans G, Eppel W, Wenzl R. Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertil Steril 2004; 81(1):132-136.
63. Wu T, Chen X, Xie L. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev 2007; (4): CD005287.
64. Bulun SE, Imir G, Utsunomiya H, et al. Aromatase in endometri-osis and uterine leiomyomata. J Steroid Biochem Mol Biol 2005; 95(1-5): 57-62.
65. Ishikawa H, Reierstad S, Demura M, et al. High aromatase expression in uterine leiomyoma tissues of African-American women. J Clin Endocrinol Metab 2009; 94(5): 1752-1756.
66. Parsanezhad ME, Azmoon M, Alborzi S, et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptore-lin) on uterine leiomyoma volume and hormonal status. Fertil Steril 2010; 93(1): 192-198.
67. Hilario SG, Bozzini N, Borsari R, Baracat EC. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. Fertil Steril 2009; 91(1): 240-243.
68. Varelas FK, Papanicolaou AN, Vavatsi-Christaki N, Makedos GA, Vlassis GD. The effect of anastrazole on symptomatic uterine leiomyomata. Obstet Gynecol 2007; 110(3): 643-649.
69. Ravina JH, Herbreteau D, Ciraru-Vigneron N, et al. Arterial em-bolisation to treat uterine myomata. Lancet 1995; 346(8976): 671-672.
70. Bradley LD. Uterine fibroid embolization: a viable alternative to hysterectomy. Am J Obstet Gynecol 2009; 201(2): 127-135.
71. Goodwin SC, Spies JB. Uterine fibroid embolization. N Engl J Med 2009; 361(7): 690-697.
72. Andrews RT, Spies JB, Sacks D, et al. Patient care and uterine artery embolization for leiomyomata. J Vasc Interv Radiol 2009; 20(7 Suppl): S307-S311.
73. Hovsepian DM, Siskin GP, Bonn J, et al. Quality improvement guidelines for uterine artery embolization for symptomatic leio-myomata. J Vasc Interv Radiol 2009; 20(7 Suppl): S193-S199.
74. Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines. Uterine fibroid embolization (UFE). Number 150, 2004. Int J Gynaecol Obstet 2005; 89(3): 305-318.
75. Dutton S, Hirst A, McPherson K, Nicholson T, Maresh M. A UK multicentre retrospective cohort study comparing hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids (HOPEFUL study): main results on medium-term safety and efficacy. BJOG 2007; 114(11): 1340-1351. *This is one of the large cohort study comparing hysterectomy and UAE.
76. Worthington-Kirsch R, Spies JB, et al. The Fibroid Registry for outcomes data (FIBROID) for uterine embolization: short-term outcomes. ObstetGynecol 2005; 106(1): 52-59. *This paper reviewed the short-term outcomes data in patients who underwent UAE from the FIBROID registry.
77. Spies JB, Spector A, Roth AR, Baker CM, Mauro L, Murphy-Skrynarz K. Complications after uterine artery embolization for leiomyomas. Obstet Gynecol 2002; 100(5 Pt 1): 873-880.
78. Hehenkamp WJ, Volkers NA, Birnie E, Reekers JA, Ankum WM. Symptomatic uterine fibroids: treatment with uterine artery emboli-zation or hysterectomy--results from the randomized clinical Em-bolisation versus Hysterectomy (EMMY) Trial. Radiology 2008; 246(3): 823-832. *EMMY trial is another large randomized trial compared the outcome of UAE and hysterectomy.
79. Hirst A, Dutton S, Wu O, et al. A multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids. The HOPEFUL study. Health Tech-nol Assess 2008;12(5): 1-248, iii. *HOPEFUL study is another large cohort study compared outcomes of UAE and hysterectomy
80. Vashisht A, Studd J, Carey A, Burn P. Fatal septicaemia after fibroid embolisation. Lancet 199924; 354(9175): 307-308.
81. de Blok S, de Vries C, Prinssen HM, Blaauwgeers HL, Jorna-Meijer LB. Fatal sepsis after uterine artery embolization with mi-crospheres. J Vasc Interv Radiol 2003;14(6): 779-783.
82. Fatal nontarget embolization via an intrafibroid arterial venous fistula during uterine fibroid embolization. J Vasc Interv Radiol 2009; 20(3): 419-420.
83. Smeets AJ, Lohle PN, Vervest HA, Boekkooi PF, Lampmann LE. Mid-term clinical results and patient satisfaction after uterine artery embolization in women with symptomatic uterine fibroids. Cardio-vasc Intervent Radiol 2006; 29(2): 188-191.
84. Smith WJ, Upton E, Shuster EJ, Klein AJ, Schwartz ML. Patient satisfaction and disease specific quality of life after uterine artery embolization. Am J Obstet Gynecol 2004; 190(6): 1697-703; discussion 1703-1706.
85. Spies JB, Benenati JF, Worthington-Kirsch RL, Pelage JP. Initial experience with use of tris-acryl gelatin microspheres for uterine artery embolization for leiomyomata. J Vasc Interv Radiol 2001;12(9): 1059-1063.
86. Pron G, Bennett J, Common A, Wall J, Asch M, Sniderman K, et al. The Ontario Uterine Fibroid Embolization Trial. Part 2. Uterine fibroid reduction and symptom relief after uterine artery emboliza-tion for fibroids. Fertil Steril 2003; 79(1): 120-127.
87. Voogt MJ, De Vries J, Fonteijn W, Lohle PN, Boekkooi PF. Sexual functioning and psychological well-being after uterine artery em-bolization in women with symptomatic uterine fibroids. Fertil Steril 2009; 92(2): 756-761.
88. Goodwin SC, Spies JB, Worthington-Kirsch R, et al. Uterine artery embolization for treatment of leiomyomata: long-term outcomes from the FIBROID Registry. Obstet Gynecol 2008; 111(1): 22-33.
89. Spies JB, Bruno J, Czeyda-Pommersheim F, Magee ST, Ascher SA, Jha RC. Long-term outcome of uterine artery embolization of leiomyomata. Obstet Gynecol 2005; 106 (5 Pt 1): 933-939.
90. Volkers NA, Hehenkamp WJ, Birnie E, Ankum WM, Reekers JA. Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids: 2 years' outcome from the randomized EMMY trial. Am J Obstet Gynecol 2007; 196(6): 519.e1-519.11.
91. Walker WJ, Barton-Smith P. Long-term follow up of uterine artery embolisation--an effective alternative in the treatment of fibroids. BJOG 2006; 113(4): 464-468.
92. Pinto I, Chimeno P, Romo A, et al. Uterine fibroids: uterine artery embolization versus abdominal hysterectomy for treatment--a prospective, randomized, and controlled clinical trial. Radiology 2003; 226(2): 425-431.
93. Hehenkamp WJ, Volkers NA, Donderwinkel PF, et al. Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids (EMMY trial): peri- and postprocedural results from a randomized controlled trial. Am J Obstet Gynecol 2005; 193(5): 1618-1629.
94. Volkers NA, Hehenkamp WJ, Birnie E, et al. Uterine artery em-bolization in the treatment of symptomatic uterine fibroid tumors (EMMY trial): periprocedural results and complications. J Vasc In-terv Radiol 2006; 17(3): 471-480.
95. Katsumori T, Kasahara T. Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids (EMMY trial). Am J Obstet Gynecol 2006;195(4):1190; author reply 1191.
96. Hehenkamp WJ, Volkers NA, Birnie E, Reekers JA, Ankum WM. Pain and return to daily activities after uterine artery embolization and hysterectomy in the treatment of symptomatic uterine fibroids: results from the randomized EMMY trial. Cardiovasc Intervent Radiol 2006; 29(2): 179-187.
97. Volkers NA, Hehenkamp WJ, Smit P, Ankum WM, Reekers JA, Birnie E. Economic evaluation of uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids: results from the randomized EMMY trial. J Vasc Interv Radiol 2008; 19(7): 1007-1016; quiz 1017.
98. Edwards RD, Moss JG, Lumsden MA, et al. Uterine-artery emboli-zation versus surgery for symptomatic uterine fibroids. N Engl J Med 2007; 356(4): 360-370. *This is another large trial compared the outcomes between surgery and UAE.
99. Goodwin SC, Bradley LD, Lipman JC, et al. Uterine artery emboli-zation versus myomectomy: a multicenter comparative study. Fertil Steril 2006; 85(1): 14-21. *This study is one of the few studies compared the outcomes of myomectomy and UAE.
100. Mara M, Maskova J, Fucikova Z, Kuzel D, Belsan T, Sosna O. Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myo-mectomy. Cardiovasc Intervent Radiol 2008; 31(1): 73-85. **This is currently the only randomized controlled trial focusing on the reproductive outcomes between myomectomy and UAE.
101. Walker WJ, Pelage JP. Uterine artery embolisation for symptomatic fibroids: clinical results in 400 women with imaging follow up. BJOG 2002; 109(11): 1262-1272.
102. Spies JB, Myers ER, Worthington-Kirsch R, et al. The FIBROID Registry: symptom and quality-of-life status 1 year after therapy. Obstet Gynecol 2005; 106(6): 1309-1318.
103. Katsumori T, Kasahara T, Tsuchida Y, Nozaki T. Amenorrhea and resumption of menstruation after uterine artery embolization for fibroids. Int J Gynaecol Obstet 2008; 103(3): 217-221.
104. Tropeano G, Di Stasi C, Litwicka K, Romano D, Draisci G, Man-cuso S. Uterine artery embolization for fibroids does not have adverse effects on ovarian reserve in regularly cycling women younger than 40 years. Fertil Steril 2004; 81(4): 1055-1061.
105. Spies JB, Roth AR, Gonsalves SM, Murphy-Skrzyniarz KM. Ovarian function after uterine artery embolization for leiomyomata: assessment with use of serum follicle stimulating hormone assay. J Vasc Interv Radiol 2001; 12(4): 437-442.
106. Healey S, Buzaglo K, Seti L, Valenti D, Tulandi T. Ovarian function after uterine artery embolization and hysterectomy. J Am As-soc Gynecol Laparosc 2004; 11(3): 348-352.
107. Pinto Pabon I, Magret JP, Unzurrunzaga EA, Garcia IM, Catalan IB, Cano Vieco ML. Pregnancy after uterine fibroid embolization: follow-up of 100 patients embolized using tris-acryl gelatin micro-spheres. Fertil Steril 2008; 90(6): 2356-2360.
108. Carpenter TT, Walker WJ. Pregnancy following uterine artery embolisation for symptomatic fibroids: a series of 26 completed pregnancies. BJOG 2005; 112(3): 321-325.
109. Walker WJ, McDowell SJ. Pregnancy after uterine artery emboliza-tion for leiomyomata: a series of 56 completed pregnancies. Am J Obstet Gynecol 2006; 195(5): 1266-1271.
110. Pron G, Mocarski E, Bennett J, et al. Pregnancy after uterine artery embolization for leiomyomata: the Ontario multicenter trial. Obstet Gynecol 2005; 105(1): 67-76.
111. Ravina JH, Vigneron NC, Aymard A, Le Dref O, Merland JJ. Pregnancy after embolization of uterine myoma: report of 12 cases. Fertil Steril 2000;73(6):1241-1243.
112. Price N, Gillmer MD, Stock A, Hurley PA. Pregnancy following uterine artery embolisation. J Obstet Gynaecol 2005; 25(1): 28-31.
113. Firouznia K, Ghanaati H, Sanaati M, Jalali AH, Shakiba M. Pregnancy after uterine artery embolization for symptomatic fibroids: a series of 15 pregnancies. AJR Am J Roentgenol 2009; 192(6): 1588-1592.
114. Holub Z, Mara M, Kuzel D, Jabor A, Maskova J, Eim J. Pregnancy outcomes after uterine artery occlusion: prospective multicentric study. Fertil Steril 2008; 90(5): 1886-1891.
115. Vidal L, Michel ME, Gavillon N, Derniaux E, Quereux C, Graesslin O. Pregnancy after uterine-artery embolization for symptomatic fibroids: a case of placenta accreta with uterine rupture. J Gynecol Obstet Biol Reprod (Paris) 2008; 37(8): 811-814.
116. Homer H, Saridogan E. Uterine artery embolization for fibroids is associated with an increased risk of miscarriage. Fertil Steril 2009. [Epub ahead of print]
117. Committee on Gynecologic Practice, American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Uterine artery embolization. Obstet Gynecol 2004; 103(2): 403-404.
118. Goldberg J, Pereira L. Pregnancy outcomes following treatment for fibroids: uterine fibroid embolization versus laparoscopic myomec-tomy. Curr Opin Obstet Gynecol 2006; 18(4): 402-406.
119. Hald K, Klow NE, Qvigstad E, Istre O. Laparoscopic occlusion compared with embolization of uterine vessels: a randomized controlled trial. Obstet Gynecol 2007; 109(1): 20-27.
120. Lichtinger M, Herbert S, Memmolo A. Temporary, transvaginal occlusion of the uterine arteries: a feasibility and safety study. J Minim Invasive Gynecol 2005; 12(1): 40-42.
121. Hald K, Klow NE, Qvigstad E, Istre O. Treatment of uterine myomas with transvaginal uterine artery occlusion: possibilities and limitations. J Minim Invasive Gynecol 2008; 15(5): 631-635.
122. Vilos GA, Vilos EC, Romano W, Abu-Rafea B. Temporary uterine artery occlusion for treatment of menorrhagia and uterine fibroids using an incisionless Doppler-guided transvaginal clamp: case report. Hum Reprod 2006; 21(1): 269-271.
123. Bradley WG. MR-guided focused ultrasound: a potentially disruptive technology. J Am Coll Radiol 2009; 6(7): 510-513.
124. Hindley J, Gedroyc WM, Regan L, et al. MRI guidance of focused ultrasound therapy of uterine fibroids: early results. AJR Am J Roentgenol 2004; 183(6): 1713-1719. **This is the pivotal study for the MRgFUS.
125. Stewart EA, Rabinovici J, Tempany CM, et al. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. Fertil Steril 2006; 85(1): 22-29.
126. Stewart EA, Gedroyc WM, Tempany CM, et al. Focused ultrasound treatment of uterine fibroid tumors: safety and feasibility of a noninvasive thermoablative technique. Am J Obstet Gynecol 2003; 189(1): 48-54.
127. Fennessy FM, Tempany CM, McDannold NJ, et al. Uterine leio-myomas: MR imaging-guided focused ultrasound surgery--results of different treatment protocols. Radiology 2007; 243(3): 885-893.
128. Stewart EA, Gostout B, Rabinovici J, Kim HS, Regan L, Tempany CM. Sustained relief of leiomyoma symptoms by using focused ultrasound surgery. Obstet Gynecol 2007; 110(2 Pt 1): 279-287. * This study reports the outcomes after 2 years of MRgFUS treatments.
129. Shen SH, Fennessy F, McDannold N, Jolesz F, Tempany C. Image-guided thermal therapy of uterine fibroids. Semin Ultrasound CT MR 2009; 30(2): 91-104.
130. Smart OC, Hindley JT, Regan L, Gedroyc WG. Gonadotrophin-releasing hormone and magnetic-resonance-guided ultrasound surgery for uterine leiomyomata. Obstet Gynecol 2006; 108(1): 49-54.
131. Gavrilova-Jordan LP, Rose CH, Traynor KD, Brost BC, Gostout BS. Successful term pregnancy following MR-guided focused ultrasound treatment of uterine leiomyoma. J Perinatol 2007; 27(1): 59-61.
132. Hanstede MM, Tempany CM, Stewart EA. Focused ultrasound surgery of intramural leiomyomas may facilitate fertility: a case report. Fertil Steril 2007; 88(2): 497.e5-497.e7.
133. Morita Y, Ito N, Ohashi H. Pregnancy following MR-guided focused ultrasound surgery for a uterine fibroid. Int J Gynaecol Ob-stet 2007; 99(1): 56-57.
134. Rabinovici J, Inbar Y, Eylon SC, Schiff E, Hananel A, Freundlich D. Pregnancy and live birth after focused ultrasound surgery for symptomatic focal adenomyosis: a case report. Hum Reprod 2006; 21(5): 1255-1259.
135. Rabinovici J, David M, Fukunishi H, et al. Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids. Fertil Steril 2010; 93(1): 199-209.
136. Young SL, Al-Hendy A, Copland JA. Potential nonhormonal therapeutics for medical treatment of leiomyomas. Semin Reprod Med 2004; 22(2): 121-130.
137. Lee BS, Stewart EA, Sahakian M, Nowak RA. Interferon-alpha is a potent inhibitor of basic fibroblast growth factor-stimulated cell proliferation in human uterine cells. Am J Reprod Immunol 1998; 40(1): 19-25.
138. Minakuchi K, Kawamura N, Tsujimura A, Ogita S. Remarkable and persistent shrinkage of uterine leiomyoma associated with in-terferon alfa treatment for hepatitis. Lancet 1999; 353(9170): 2127-2128.
139. Nowak RA. Novel therapeutic strategies for leiomyomas: targeting growth factors and their receptors. Environ Health Perspect 2000; 108 (Suppl 5): 849-853.
140. Grudzien MM, Low PS, Manning PC, Arredondo M, Belton RJ, Jr, Nowak RA. The antifibrotic drug halofuginone inhibits proliferation and collagen production by human leiomyoma and myometrial smooth muscle cells. Fertil Steril 2010; 93(4): 1290-1298.
141. Loy CJ, Evelyn S, Lim FK, Liu MH, Yong EL. Growth dynamics of human leiomyoma cells and inhibitory effects of the peroxisome proliferator-activated receptor-gamma ligand, pioglitazone. Mol Hum Reprod 2005; 11(8): 561-566.
142. Al-Hendy A, Salama S. Gene therapy and uterine leiomyoma: a review. Hum Reprod Update 2006; 12(4): 385-400.
143. Hassan M, Zhang D, Salama S, et al. Towards fibroid gene therapy: adenovirus-mediated delivery of herpes simplex virus 1 thymidine kinase gene/ganciclovir shrinks uterine leiomyoma in the Eker rat model. Gynecol Obstet Invest 2009; 68(1): 19-32.
144. Hassan MH, Salama SA, Zhang D, et al. Gene therapy targeting leiomyoma: adenovirus-mediated delivery of dominant-negative estrogen receptor gene shrinks uterine tumors in Eker rat model. Fertil Steril 2010; 93(1): 239-250.